A Phase 1b/Phase 2 study of PNT001 in patients with Alzheimer's disease
Latest Information Update: 23 Jun 2021
At a glance
- Drugs PNT 001 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pinteon Therapeutics
- 23 Jun 2021 New trial record
- 17 Jun 2021 According to a Pinteon Therapeutics media release, this study is expected to begin by the end of 2021.